LYRA vs. DXR, NEPH, SPAI, MODD, ECOR, QTI, POCI, PYPD, NMTC, and TMDIF
Should you be buying Lyra Therapeutics stock or one of its competitors? The main competitors of Lyra Therapeutics include Daxor (DXR), Nephros (NEPH), Safe Pro Group (SPAI), Modular Medical (MODD), electroCore (ECOR), QT Imaging (QTI), Precision Optics (POCI), PolyPid (PYPD), NeuroOne Medical Technologies (NMTC), and Titan Medical (TMDIF). These companies are all part of the "medical equipment" industry.
Lyra Therapeutics vs. Its Competitors
Lyra Therapeutics (NASDAQ:LYRA) and Daxor (NASDAQ:DXR) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings, valuation and media sentiment.
Lyra Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500. Comparatively, Daxor has a beta of -0.07, suggesting that its share price is 107% less volatile than the S&P 500.
Daxor has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -6,711.39%. Daxor's return on equity of 0.00% beat Lyra Therapeutics' return on equity.
Lyra Therapeutics currently has a consensus price target of $100.00, suggesting a potential upside of 1,009.26%. Daxor has a consensus price target of $25.00, suggesting a potential upside of 154.32%. Given Lyra Therapeutics' higher possible upside, equities analysts clearly believe Lyra Therapeutics is more favorable than Daxor.
95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 1.3% of Daxor shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by insiders. Comparatively, 59.5% of Daxor shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
In the previous week, Lyra Therapeutics had 1 more articles in the media than Daxor. MarketBeat recorded 1 mentions for Lyra Therapeutics and 0 mentions for Daxor. Lyra Therapeutics' average media sentiment score of 0.49 beat Daxor's score of 0.00 indicating that Lyra Therapeutics is being referred to more favorably in the media.
Daxor has lower revenue, but higher earnings than Lyra Therapeutics.
Summary
Lyra Therapeutics beats Daxor on 6 of the 11 factors compared between the two stocks.
Get Lyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYRA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LYRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyra Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:LYRA) was last updated on 7/7/2025 by MarketBeat.com Staff
